Pacira BioSciences Return on Equity

Pacira BioSciences (PCRX) currently reports a ROE of 6.94%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Pacira BioSciences's ROE history and peer comparisons.

Pacira BioSciences's ROE of 6.94% is lower than the Healthcare sector average of 20.86%. That is roughly 66.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Pacira BioSciences's current 6.94% should be judged against Healthcare norms (sector average: 20.86%) and against PCRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 6.94%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Pacira BioSciences, and consider following PCRX for alerts when major investors trade the stock.

Pacira BioSciences is classified in the Healthcare sector. On ROE, it currently shows 6.94% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PCRX with unrelated industries.